Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.

MLA

Abbadessa, Gianmarco, et al. “Previous Disease-Modifying Treatments Influence T Lymphocyte Kinetics in People with Multiple Sclerosis Switching to Ocrelizumab.” Journal of Neuroimmunology, vol. 378, May 2023, p. 578072. EBSCOhost, https://doi.org/10.1016/j.jneuroim.2023.578072.

APA

Abbadessa, G., Miele, G., Cavalla, P., Valentino, P., Marfia, G. A., Vercellino, M., De Martino, A., Simeon, V., Lavorgna, L., & Bonavita, S. (2023). Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab. Journal of Neuroimmunology, 378, 578072. https://doi.org/10.1016/j.jneuroim.2023.578072

Chicago

Abbadessa, Gianmarco, Giuseppina Miele, Paola Cavalla, Paola Valentino, Girolama Alessandra Marfia, Marco Vercellino, Antonio De Martino, Vittorio Simeon, Luigi Lavorgna, and Simona Bonavita. 2023. “Previous Disease-Modifying Treatments Influence T Lymphocyte Kinetics in People with Multiple Sclerosis Switching to Ocrelizumab.” Journal of Neuroimmunology 378 (May): 578072. doi:10.1016/j.jneuroim.2023.578072.